about
Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytesDetermination of the Plk4/Sak consensus phosphorylation motif using peptide spots arraysCancer immunotherapy: the beginning of the end of cancer?Nck proteins maintain the adult glomerular filtration barrier.Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.Strategies for discovering novel pancreatic cancer biomarkers.Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissuesThe long journey of cancer biomarkers from the bench to the clinic.Miniaturization: The future of laboratory medicine.False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.Phosphorylated YDXV motifs and Nck SH2/SH3 adaptors act cooperatively to induce actin reorganization.Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity.Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.Analytical evaluation of the BioPlex® 2200 25-OH vitamin D total assayAnalytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervalsPediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer—A CALIPER pilot study
P50
Q24299126-554820BB-1C57-4EB3-85F8-9100BB9DE78CQ24307359-489AF868-F513-4205-8B97-F4BB0D227880Q24337207-055CF551-79AC-488A-917E-31D07975A452Q26752277-A3665D13-717E-4FA4-B993-01388D3F8A1FQ30157251-5AF6CEEF-6C07-4376-9EBA-637B81A2A726Q34518517-5366DB48-B09B-486A-B8F9-FB1062236BBDQ34979033-8A636DB1-CD5B-4D48-BC11-D3FFF5DA37DEQ35797487-5B61C6C0-D018-4414-B6EF-02486FD02A02Q35909576-DCAA23BC-B922-41D6-B268-9C5FC9FB32BBQ36579311-427D3D4E-FA98-4EEC-8A71-D28738850692Q37214680-1293B1D3-A44B-4CE6-97BA-54AF1E691679Q38047281-F3FCBB9E-440B-4832-8E7B-87E8EE799CDFQ38939299-719D3323-ECBA-4677-9366-84D417B3D06BQ39085603-4EB51C58-9B55-4924-A502-11EB63D591B8Q41845103-52865D48-F4C1-4876-ADED-D790C1DB2399Q45843054-1B078251-98B2-4568-8A07-1EF759BECB29Q53818558-F07C2951-5CE6-40CC-9AF2-CFA1C3090AACQ58542984-0330604B-848C-4B0F-81A8-2259985C38FFQ58543156-8B342C40-3B8D-4D55-8371-20F96A7FC8AFQ58543180-C7D2F688-2747-4FDA-BC32-27DD66E19D6D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ivan Blasutig
@ast
Ivan Blasutig
@en
Ivan Blasutig
@es
Ivan Blasutig
@nl
Ivan Blasutig
@sl
type
label
Ivan Blasutig
@ast
Ivan Blasutig
@en
Ivan Blasutig
@es
Ivan Blasutig
@nl
Ivan Blasutig
@sl
prefLabel
Ivan Blasutig
@ast
Ivan Blasutig
@en
Ivan Blasutig
@es
Ivan Blasutig
@nl
Ivan Blasutig
@sl
P106
P1153
12806270900
P21
P31
P496
0000-0001-7310-2647